EDP Sciences logo
Subscriber Authentication Point
Search
Menu
Home All issues Volume 32 / No 8-9 (Août–Septembre 2016) Med Sci (Paris), 32 8-9 (2016) 739-745 References
Free Access
Issue
Med Sci (Paris)
Volume 32, Number 8-9, Août–Septembre 2016
Page(s) 739 - 745
Section M/S Revues
DOI https://doi.org/10.1051/medsci/20163208022
Published online 12 September 2016
  1. Ott JJ, Stevens GA, Groeger J, Wiersma ST. Global epidemiology of hepatitis B virus infection: new estimates of age-specific HBsAg seroprevalence and endemicity. Vaccine 2012 ; 30 : 2212–2219. [CrossRef] [PubMed] [Google Scholar]
  2. Ganem D, Prince AM. Hepatitis B virus infection: natural history and clinical consequences. N Engl J Med 2004 ; 350 : 1118–1129. [CrossRef] [PubMed] [Google Scholar]
  3. Shimakawa Y, Lemoine M, Njai HF, et al. Natural history of chronic HBV infection in West Africa: a longitudinal population-based study from The Gambia. Gut 2015 ; pii: gutjnl-2015-309892. doi : 10.1136/gutjnl-2015-309892. [Google Scholar]
  4. Stevens CE, Beasley RP, Tsui J, Lee WC. Vertical transmission of hepatitis B antigen in Taiwan. N Engl J Med 1975 ; 292 : 771–774. [CrossRef] [PubMed] [Google Scholar]
  5. Beasley RP, Hwang LY, Lin CC, et al. Incidence of hepatitis B virus infections in preschool children in Taiwan. J Infect Dis 1982 ; 146 : 198–204. [CrossRef] [PubMed] [Google Scholar]
  6. Sarkar M, Terrault NA. Ending vertical transmission of hepatitis B: the third trimester intervention. Hepatology 2014 ; 60 : 448–451. [CrossRef] [PubMed] [Google Scholar]
  7. Maupas P, Goudeau A, Coursaget P, et al. Hepatitis B vaccine: efficacy in high-risk settings, a two-year study. Intervirology 1978 ; 10 : 196–208. [CrossRef] [PubMed] [Google Scholar]
  8. Galibert F, Mandart E, Fitoussi F, et al. Nucleotide sequence of the hepatitis B virus genome (subtype ayw) cloned in E. coli. Nature 1979 ; 281 : 646–650. [CrossRef] [PubMed] [Google Scholar]
  9. Pasek M, Goto T, Gilbert W, et al. Hepatitis B virus genes and their expression in E. coli. Nature 1979 ; 282 : 575–579. [CrossRef] [PubMed] [Google Scholar]
  10. Valenzuela P, Medina A, Rutter WJ, et al. Synthesis and assembly of hepatitis B virus surface antigen particles in yeast. Nature 1982 ; 298 : 347–350. [CrossRef] [PubMed] [Google Scholar]
  11. Michel ML, Pontisso P, Sobczak E, et al. Synthesis in animal cells of hepatitis B surface antigen particles carrying a receptor for polymerized human serum albumin. Proc Natl Acad Sci USA 1984 ; 81 : 7708–7712. [CrossRef] [Google Scholar]
  12. Chiang CJ, Yang YW, You SL, et al. Thirty-year outcomes of the national hepatitis B immunization program in Taiwan. JAMA 2013 ; 310 : 974–976. [CrossRef] [PubMed] [Google Scholar]
  13. Chang MH, You SL, Chen CJ, et al. Decreased incidence of hepatocellular carcinoma in hepatitis B vaccinees: a 20-year follow-up study. J Natl Cancer Inst 2009 ; 101 : 1348–1355. [CrossRef] [PubMed] [Google Scholar]
  14. Tajiri H, Tanaka H, Brooks S, Takano T. Reduction of hepatocellular carcinoma in childhood after introduction of selective vaccination against hepatitis B virus for infants born to HBV carrier mothers. Cancer Causes Control 2011 ; 22 : 523–527. [CrossRef] [PubMed] [Google Scholar]
  15. McMahon BJ, Bulkow LR, Singleton RJ, et al. Elimination of hepatocellular carcinoma and acute hepatitis B in children 25 years after a hepatitis B newborn and catch-up immunization program. Hepatology 2011 ; 54 : 801–807. [CrossRef] [PubMed] [Google Scholar]
  16. Qu C, Chen T, Fan C, et al. Efficacy of neonatal HBV vaccination on liver cancer and other liver diseases over 30-year follow-up of the Qidong hepatitis B intervention study: a cluster randomized controlled trial. PLoS Med 2014 ; 11 : e1001774. [CrossRef] [PubMed] [Google Scholar]
  17. Werner JM, Abdalla A, Gara N, et al. The hepatitis B vaccine protects re-exposed health care workers, but does not provide sterilizing immunity. Gastroenterology 2013 ; 145 : 1026–1034. [CrossRef] [PubMed] [Google Scholar]
  18. Li ZK, Nie JJ, Li J, Zhuang H. The effect of HLA on immunological response to hepatitis B vaccine in healthy people: a meta-analysis. Vaccine 2013 ; 31 : 4355–4361. [CrossRef] [PubMed] [Google Scholar]
  19. Launay O, van der Vliet D, Rosenberg AR, et al. Safety and immunogenicity of 4 intramuscular double doses and 4 intradermal low doses vs standard hepatitis B vaccine regimen in adults with HIV-1: a randomized controlled trial. JAMA 2011 ; 305 : 1432–1440. [CrossRef] [PubMed] [Google Scholar]
  20. Rey D, Piroth L, Wendling MJ, et al. Safety and immunogenicity of double-dose versus standard-dose hepatitis B revaccination in non-responding adults with HIV-1 (ANRS HB04 B-BOOST): a multicentre, open-label, randomised controlled trial. Lancet Infect Dis 2015 ; 15 : 1283–1291. [CrossRef] [PubMed] [Google Scholar]
  21. Kong NC, Beran J, Kee SA, et al. A new adjuvant improves the immune response to hepatitis B vaccine in hemodialysis patients. Kidney Int 2008 ; 73 : 856–862. [CrossRef] [PubMed] [Google Scholar]
  22. Filippelli M, Lionetti E, Gennaro A, et al. Hepatitis B vaccine by intradermal route in non responder patients: an update. World J Gastroenterol 2014 ; 20 : 10383–10394. [CrossRef] [PubMed] [Google Scholar]
  23. Krawczyk A, Ludwig C, Jochum C, et al. Induction of a robust T- and B-cell immune response in non- and low-responders to conventional vaccination against hepatitis B by using a third generation PreS/S vaccine. Vaccine 2014 ; 32 : 5077–5082. [CrossRef] [PubMed] [Google Scholar]
  24. Zanetti AR, Mariano A, Romano L, et al. Long-term immunogenicity of hepatitis B vaccination and policy for booster: an Italian multicentre study. Lancet 2005 ; 366 : 1379–1384. [CrossRef] [PubMed] [Google Scholar]
  25. Lu CY, Ni YH, Chiang BL, et al. Humoral and cellular immune responses to a hepatitis B vaccine booster 15–18 years after neonatal immunization. J Infect Dis 2008 ; 197 : 1419–1426. [CrossRef] [PubMed] [Google Scholar]
  26. Are booster immunisations needed for lifelong hepatitis B immunity? European Consensus Group on Hepatitis B Immunity. Lancet 2000 ; 355 : 561–565. [CrossRef] [PubMed] [Google Scholar]
  27. Romano L, Paladini S, Galli C, et al. Hepatitis B vaccination. Hum Vaccin Immunother 2015 ; 11 : 53–57. [CrossRef] [Google Scholar]
  28. Hsu HY, Chang MH, Ni YH, et al. No increase in prevalence of hepatitis B surface antigen mutant in a population of children and adolescents who were fully covered by universal infant immunization. J Infect Dis 2010 ; 201 : 1192–1200. [CrossRef] [PubMed] [Google Scholar]
  29. Locarnini S, Shouval D. Commonly found variations/mutations in the HBsAg of hepatitis B virus in the context of effective immunization programs: questionable clinical and public health significance. J Virol 2014 ; 88 : 6532. [CrossRef] [PubMed] [Google Scholar]
  30. Launay O, Floret D. Vaccination contre l’hépatite B. Med Sci (Paris) 2015 ; 31 : 551–558. [CrossRef] [EDP Sciences] [Google Scholar]
  31. Denis F, Cohen R, Martinot A, et al. Evolution of hepatitis B vaccine coverage rates in France between 2008 and 2011. Med Mal Infect 2013 ; 43 : 272–278. [CrossRef] [PubMed] [Google Scholar]
  32. Antona D, Lefort MJ, Larsen C, Levy-Bruhl D. L’infection par le virus de l’hépatite B : une maladie sexuellement transmissible. Bull Epidemiol Hebd 2011 ; 26–27-28 : 307–310. [Google Scholar]
  33. Stahl JP, Denis F, Gaudelus J, et al. Hepatitis B vaccination and adolescents: a lost generation. Med Mal Infect 2016 ; 46 : 1–3. [CrossRef] [PubMed] [Google Scholar]
  34. Liang TJ, Block TM, McMahon BJ, et al. Present and future therapies of hepatitis B: from discovery to cure. Hepatology 2015 ; 62 : 1893–1908. [CrossRef] [PubMed] [Google Scholar]
  35. Rehermann B, Nascimbeni M. Immunology of hepatitis B virus and hepatitis C virus infection. Nat Rev Immunol 2005 ; 5 : 215–229. [CrossRef] [PubMed] [Google Scholar]
  36. Couillin I, Pol S, Mancini M, et al. Specific vaccine therapy in chronic hepatitis B: induction of T cell proliferative responses specific for envelope antigens. J Infect Dis 1999 ; 180 : 15–26. [CrossRef] [PubMed] [Google Scholar]
  37. Michel ML, Deng Q, Mancini-Bourgine M. Therapeutic vaccines and immune-based therapies for the treatment of chronic hepatitis B: perspectives and challenges. J Hepatol 2011 ; 54 : 1286–1296. [CrossRef] [PubMed] [Google Scholar]
  38. Mancini-Bourgine M, Fontaine H, Scott-Algara D, et al. Induction or expansion of T-cell responses by a hepatitis B DNA vaccine administered to chronic HBV carriers. Hepatology 2004 ; 40 : 874–882. [CrossRef] [PubMed] [Google Scholar]
  39. Protzer U, Maini MK, Knolle PA. Living in the liver: hepatic infections. Nat Rev Immunol 2012 ; 12 : 201–213. [CrossRef] [PubMed] [Google Scholar]
  40. Martin P, Dubois C, Jacquier E, et al. TG1050, an immunotherapeutic to treat chronic hepatitis B, induces robust T cells and exerts an antiviral effect in HBV-persistent mice. Gut 2015 ; 64 : 1961–1971. [CrossRef] [PubMed] [Google Scholar]
  41. Liu J, Zhang E, Ma Z, et al. Enhancing virus-specific immunity in vivo by combining therapeutic vaccination and PD-L1 blockade in chronic hepadnaviral infection. PLoS Pathog 2014 ; 10 : e1003856. [CrossRef] [PubMed] [Google Scholar]
  42. Testoni B, Zoulim F. Liver capsule: validated and potential novel targets to treat hepatitis B virus. Hepatology 2015 ; 62 : 1619. [CrossRef] [PubMed] [Google Scholar]
  43. Zeisel MB, Lucifora J, Mason WS, et al. Towards an HBV cure: state-of-the-art and unresolved questions. Report of the ANRS workshop on HBV cure. Gut 2015 ; 64 : 1314–1326. [CrossRef] [PubMed] [Google Scholar]
  44. Launay O, Floret D. Vaccination contre l’hépatite B. Med Sci (Paris) 2015 ; 31 : 551–558. [CrossRef] [EDP Sciences] [Google Scholar]
  45. Floret D. Les résistances à la vaccination. Med Sci (Paris) 2010 ; 26 : 1087–1093. [CrossRef] [EDP Sciences] [PubMed] [Google Scholar]

Current usage metrics show cumulative count of Article Views (full-text article views including HTML views, PDF and ePub downloads, according to the available data) and Abstracts Views on Vision4Press platform.

Data correspond to usage on the plateform after 2015. The current usage metrics is available 48-96 hours after online publication and is updated daily on week days.

Initial download of the metrics may take a while.